Centessa Pharmaceuticals Shares Gap Down to 6.56
CNTA Stock | USD 17.18 0.14 0.82% |
About 51% of Centessa Pharmaceuticals' investor base is interested to short. The analysis of the overall investor sentiment regarding Centessa Pharmaceuticals PLC suggests that many traders are impartial. The current market sentiment, together with Centessa Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Centessa Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
Centessa |
Centessa Pharmaceuticals plc s share price gapped down prior to trading on Friday . The stock had previously closed at 6.56, but opened at 6.17. Centessa Pharmaceuticals shares last traded at 6.30, with a volume of 2,255 shares traded. Wall Street Analysts Forecast Growth Several brokerages recently issued reports on CNTA.
Read at thelincolnianonline.com
Centessa Pharmaceuticals Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Centessa Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Centessa Pharmaceuticals Fundamental Analysis
We analyze Centessa Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Centessa Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Centessa Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Ratio
Current Ratio Comparative Analysis
Centessa Pharmaceuticals is currently under evaluation in current ratio category among its peers. Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Centessa Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Centessa Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Centessa Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Centessa Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Centessa Pharmaceuticals Related Equities
CCCC | C4 Therapeutics | 9.28 | ||||
IRON | Disc Medicine | 4.35 | ||||
STRO | Sutro Biopharma | 4.26 | ||||
DSGN | Design Therapeutics | 4.23 | ||||
TARS | Tarsus Pharmaceuticals | 2.94 | ||||
EWTX | Edgewise Therapeutics | 1.15 | ||||
HLVX | Hillevax | 1.02 | ||||
CRNX | Crinetics Pharmaceuticals | 0.97 | ||||
NAMSW | NewAmsterdam Pharma | 0.21 | ||||
CGEM | Cullinan Oncology | 0.24 | ||||
ERAS | Erasca | 0.67 | ||||
NUVL | Nuvalent | 1.01 | ||||
MLYS | Mineralys Therapeutics, | 1.45 | ||||
GNFT | Genfit | 2.79 | ||||
LRMR | Larimar Therapeutics | 2.81 | ||||
TRDA | Entrada Therapeutics | 2.97 | ||||
OPT | Opthea | 3.32 | ||||
IPSC | Century Therapeutics | 4.08 | ||||
GLUE | Monte Rosa | 9.85 |
Complementary Tools for Centessa Stock analysis
When running Centessa Pharmaceuticals' price analysis, check to measure Centessa Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Centessa Pharmaceuticals is operating at the current time. Most of Centessa Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Centessa Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Centessa Pharmaceuticals' price. Additionally, you may evaluate how the addition of Centessa Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |